Engineered hERG Channel Proteins for Robust Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the effects of small molecule pharmacological agents on hERG channel function are not robust, affordable, or efficient, posing a risk in drug development due to the potential for drug-induced long QT syndrome and torsade de pointes.
Innovation Solution
An engineered hERG protein with internal deletions is used in a liposome flux assay, involving a liposome and a polypeptide, with a lipophilic pH-sensitive fluorescent dye and proton ionophore to identify agents that interfere with cardiac cell repolarization by measuring fluorescence changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional hERG activity assays (electrophysiology, cell-based Tl+ flux assay, binding/inhibitor competition assay) are used, then hERG function can be evaluated, but the methods are not robust, affordable, or efficient
Solution Approach 1:
The patent replaces complex mechanical electrophysiology measurement systems with a simplified optical fluorescence detection system. The engineered hERG channel in liposomes transports ions that alter pH, which is detected through fluorescence changes of pH-sensitive dyes, eliminating the need for complex electrophysiological equipment while maintaining measurement reliability.
Solution Approach 2:
The patent creates a simplified copy of the hERG channel function by using engineered hERG channels in liposome vesicles that replicate the essential ion transport activity. This artificial system copies the key functional aspect of hERG channels without requiring intact cardiac cells or complex physiological systems, enabling high-throughput screening.
2Reliability
If engineered hERG protein with internal deletions is used, then assay robustness and efficiency are improved, but protein structure is modified
Solution Approach 1:
The patent extracts and removes specific internal segments (loops and transmembrane domains) from the full-length hERG channel protein that are not essential for ion transport function. These deleted regions are often involved in regulation, trafficking, or protein-protein interactions, allowing the creation of a minimized protein that maintains core channel activity while improving stability and expression for assay purposes.
Solution Approach 2:
The patent applies local quality modification by selectively deleting specific regions of the hERG protein while preserving the critical pore-forming and ion-conducting domains. This localized structural modification maintains the essential function in the key regions while removing problematic segments, creating a protein with optimized properties for the assay system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a robust and efficient way to assess small molecule pharmacological agents' impact on hERG function, correlating well with electrophysiological recordings and reducing the risk of drug-induced cardiac arrhythmias.
Implementation Method 1
contacting said vesicle with a proton ionophore to initiate ion flux
Implementation Method 2
measuring fluorescence
Data Source
AI summary
The present invention provides methods and compositions relating to an assay for hERG channel protein sensitivity to small molecule pharmacological agents. In one embodiment, the invention includes an engineered hERG channel protein. In another embodiment, the invention includes a method of identifying small molecule pharmacological agents that interfere with repolarization of cardiac cells.